279 related articles for article (PubMed ID: 11752443)
21. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
22. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
Sekijima Y; Dendle MA; Kelly JW
Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
[TBL] [Abstract][Full Text] [Related]
23. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
24. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
25. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
Hammarström P; Jiang X; Deechongkit S; Kelly JW
Biochemistry; 2001 Sep; 40(38):11453-9. PubMed ID: 11560493
[TBL] [Abstract][Full Text] [Related]
26. Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy.
Ferreira P; Sant'Anna R; Varejão N; Lima C; Novis S; Barbosa RV; Caldeira CM; Rumjanek FD; Ventura S; Cruz MW; Foguel D
PLoS One; 2013; 8(12):e82484. PubMed ID: 24358189
[TBL] [Abstract][Full Text] [Related]
27. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
Wiseman RL; Green NS; Kelly JW
Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
[TBL] [Abstract][Full Text] [Related]
28. Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease.
Wiseman RL; Powers ET; Kelly JW
Biochemistry; 2005 Dec; 44(50):16612-23. PubMed ID: 16342952
[TBL] [Abstract][Full Text] [Related]
29. Modulating conformational factors in transthyretin amyloid.
Saraiva MJ; Almeida MR; Alves IL; Bonifácio MJ; Damas AM; Palha JA; Goldsteins G; Lundgren E
Ciba Found Symp; 1996; 199():47-52; discussion 52-7. PubMed ID: 8915603
[TBL] [Abstract][Full Text] [Related]
30. Thermodynamic Stability and Aggregation Kinetics of EF Helix and EF Loop Variants of Transthyretin.
Ferguson JA; Sun X; Dyson HJ; Wright PE
Biochemistry; 2021 Mar; 60(10):756-764. PubMed ID: 33645214
[TBL] [Abstract][Full Text] [Related]
31. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.
Quintas A; Saraiva MJ; Brito RM
FEBS Lett; 1997 Dec; 418(3):297-300. PubMed ID: 9428731
[TBL] [Abstract][Full Text] [Related]
32. Inhibiting transthyretin amyloid fibril formation via protein stabilization.
Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762
[TBL] [Abstract][Full Text] [Related]
33. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
Sebastião MP; Lamzin V; Saraiva MJ; Damas AM
J Mol Biol; 2001 Mar; 306(4):733-44. PubMed ID: 11243784
[TBL] [Abstract][Full Text] [Related]
34. Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis.
Saito S; Ando Y; Nakamura M; Ueda M; Kim J; Ishima Y; Akaike T; Otagiri M
Biochemistry; 2005 Aug; 44(33):11122-9. PubMed ID: 16101296
[TBL] [Abstract][Full Text] [Related]
35. Structural insight into pH-induced conformational changes within the native human transthyretin tetramer.
Palaninathan SK; Mohamedmohaideen NN; Snee WC; Kelly JW; Sacchettini JC
J Mol Biol; 2008 Oct; 382(5):1157-67. PubMed ID: 18662699
[TBL] [Abstract][Full Text] [Related]
36. Pathological, biochemical, and biophysical characteristics of the transthyretin variant Y114H (p.Y134H) explain its very mild clinical phenotype.
Sekijima Y; Campos RI; Hammarström P; Nilsson KP; Yoshinaga T; Nagamatsu K; Yazaki M; Kametani F; Ikeda S
J Peripher Nerv Syst; 2015 Dec; 20(4):372-9. PubMed ID: 26306725
[TBL] [Abstract][Full Text] [Related]
37. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
Manral P; Reixach N
Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the effect of mutations and ligand binding on transthyretin homotetramer dynamics.
Saldaño TE; Zanotti G; Parisi G; Fernandez-Alberti S
PLoS One; 2017; 12(7):e0181019. PubMed ID: 28704493
[TBL] [Abstract][Full Text] [Related]
39. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
[TBL] [Abstract][Full Text] [Related]
40. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.
Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA
Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
